Fetale und neonatale Alloimmunthrombozytopenie, Teil 1

Zusammenfassung

Die fetale und neonatale Alloimmunthrombozytopenie (FNAIT) wird durch mütterliche Antikörper hervorgerufen, die gegen ein vom Vater ererbtes Blutgruppenmerkmal an fetalen Thrombozyten gerichtet sind. Teil 1 des Beitrags stellt die Ätiologie, die Pathogenese und die Diagnostik der FNAIT dar, während Teil 2 die Risikostratifizierung und Behandlung der FNAIT thematisiert [1].

Abstract

Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is a bleeding condition caused by maternal antibodies against fetal platelet antigens inherited from the father. The incidence of severe FNAIT (neonatal platelet count < 50 G/l) is 1 in 2500 live births. Its most severe consequence, intracranial hemorrhage, leading to death or neurologic disability, occurs in 10 per 100 000 neonates, commonly prior to birth. This review summarizes the current knowledge on incidence, pathogenesis, diagnosis of FNAIT in this part 1 followed by the management of pregnancies at risk and prophylaxis in part 2.

Kernaussagen

• Die fetale und neonatale Alloimmunthrombozytopenie (FNAIT) wird durch mütterliche Antikörper hervorgerufen, die gegen ein vom Vater ererbtes Blutgruppenmerkmal an fetalen Thrombozyten gerichtet sind.

• Die FNAIT wird in ca. 80% der Fälle durch mütterliche Anti-HPA-1a-Antikörper ausgelöst, gefolgt von Anti-HPA-5b Antikörpern (ca. 15%). Rund zwei Drittel der Schwangeren werden in der 1. Schwangerschaft immunisiert. Die Inzidenz der Immunisierung gegen HPA-1a wird mit 1 : 500 angegeben.

• Gefürchtet ist eine fetale intrakranielle Blutung, die eine Inzidenz von 1 : 10 000 hat. Intrakranielle Blutungen treten meist früh in der Schwangerschaft auf, in über 50% der Fälle vor der 28. Schwangerschaftswoche. Peripartale Blutungen sind selten.

• Bei Neugeborenen mit isolierter Thrombozytopenie ist eine FNAIT die wichtigste Differenzialdiagnose.

• Bei klinischem Verdacht auf eine FNAIT und negativem HPA-Antikörpersuchtest muss ein Cross-Match zwischen mütterlichem Serum und paternalen Thrombozyten durchgeführt werden.

Schlüsselwörter

fetale und neonatale Alloimmunthrombozytopenie - FNAIT - neonatale Thrombozytopenie - nichtinvasive Pränataldiagnostik

Key words

fetal and neonatal alloimmune thrombocytopenia - FNAIT - neonatal thrombocytopenia - non-invasive prenatal diagnosis

Publication History

Article published online:
01 June 2021

• Literatur

• 1 Sachs UJ, Bedei I, Wienzek-Lischka S. et al. Fetale und neonatale Alloimmunthrombozytopenie, Teil 2: Risikostratifizierung und Behandlung. Transfusionsmedizin 2021; 11: 127-142
• 2 Baker JM, Shehata N, Bussel J. et al. Postnatal intervention for the treatment of FNAIT: a systematic review. J Perinatol 2019; 39: 1329-1339 DOI: 10.1038/s41372-019-0360-7.
• 3 Philipps Universität Marburg. Dohrn, Hans Heinrich Alfred Rudolf. Professorenkatalog der Philipps-Universität Marburg. Im Internet (Stand: 14.02.2021): https://professorenkatalog.online.uni-marburg.de/de/pkat/idrec?id=10487
• 4 Dohrn R. Ein Fall von Morbus maculosus Werlhofii übertragen von der Mutter auf die Frucht. Arch Gynäkol 1874; 6: 486-487 DOI: 10.1007/BF02001246.
• 5 Harrington WJ, Sprague CC, Minnich V. et al. Immunologic mechanisms in idiopathic and neonatal thrombocytopenic purpura. Ann Intern Med 1953; 38: 433-469 DOI: 10.7326/0003-4819-38-3-433.
• 6 van Loghem JJ J, Dorfmeijer H, van Hart M. et al. Serological and genetical studies on a platelet antigen (Zw). Vox Sang 1959; 4: 161-169 DOI: 10.1111/j.1423-0410.1959.tb04032.x.
• 7 Shulman NR, Aster RH, Leitner A. et al. Immunoreactions involving platelets. V. Post-transfusion purpura due to a complement-fixing antibody against a genetically controlled platelet antigen. A proposed mechanism for thrombocytopenia and its relevance in “autoimmunity”. J Clin Invest 1961; 40: 1597-1620 DOI: 10.1172/JCI104383.
• 8 Shulman NR, Aster RH, Pearson HA. et al. Immunoreactions involving platelet. VI. Reactions of maternal isoantibodies responsible for neonatal purpura. Differentiation of a second platelet antigen system. J Clin Invest 1962; 41: 1059-1069 DOI: 10.1172/JCI104556.
• 9 Kamphuis MM, Paridaans NP, Porcelijn L. et al. Incidence and consequences of neonatal alloimmune thrombocytopenia: a systematic review. Pediatrics 2014; 133: 715-721 DOI: 10.1542/peds.2013-3320.
• 10 Kamphuis MM, Paridaans N, Porcelijn L. et al. Screening in pregnancy for fetal or neonatal alloimmune thrombocytopenia: systematic review. BJOG 2010; 117: 1335-1343 DOI: 10.1111/j.1471-0528.2010.02657.x.
• 11 Davoren A, McParland P, Barnes CA. et al. Neonatal alloimmune thrombocytopenia in the Irish population: a discrepancy between observed and expected cases. J Clin Pathol 2002; 55: 289-292 DOI: 10.1136/jcp.55.4.289.
• 12 Sachs UJ, Wienzek-Lischka S, Duong Y. et al. Maternal antibodies against paternal class I human leukocyte antigens are not associated with foetal and neonatal alloimmune thrombocytopenia. Br J Haematol 2020; 189: 751-759 DOI: 10.1111/bjh.16419.
• 13 Tiller H, Kamphuis MM, Flodmark O. et al. Fetal intracranial haemorrhages caused by fetal and neonatal alloimmune thrombocytopenia: an observational cohort study of 43 cases from an international multicentre registry. BMJ Open 2013; 3 DOI: 10.1136/bmjopen-2012-002490.
• 14 Versiti. HPA Database (Oktober 2020). Im Internet (Stand: 13.05.2021): https://www.versiti.org/hpa
• 15 Ghevaert C, Campbell K, Walton J. et al. Management and outcome of 200 cases of fetomaternal alloimmune thrombocytopenia. Transfusion 2007; 47: 901-910 DOI: 10.1111/j.1537-2995.2007.01208.x.
• 16 Kroll H, Yates J, Santoso S. Immunization against a low-frequency human platelet alloantigen in fetal alloimmune thrombocytopenia is not a single event: characterization by the combined use of reference DNA and novel allele-specific cell lines expressing recombinant antigens. Transfusion 2005; 45: 353-358 DOI: 10.1111/j.1537-2995.2005.04218.x.
• 17 Davoren A, Curtis BR, Aster RH. et al. Human platelet antigen-specific alloantibodies implicated in 1162 cases of neonatal alloimmune thrombocytopenia. Transfusion 2004; 44: 1220-1225 DOI: 10.1111/j.1537-2995.2004.04026.x.
• 18 Ohto H, Miura S, Ariga H. et al. The natural history of maternal immunization against foetal platelet alloantigens. Transfus Med 2004; 14: 399-408 DOI: 10.1111/j.1365-3148.2004.00535.x.
• 19 Tomiyama Y, Take H, Ikeda H. et al. Identification of the platelet-specific alloantigen, Naka, on platelet membrane glycoprotein IV. Blood 1990; 75: 684-687
• 20 Curtis BR, Aster RH. Incidence of the Nak(a)-negative platelet phenotype in African Americans is similar to that of Asians. Transfusion 1996; 36: 331-334 DOI: 10.1046/j.1537-2995.1996.36496226147.x.
• 21 Mueller-Eckhardt C, Kiefel V, Grubert A. et al. 348 cases of suspected neonatal alloimmune thrombocytopenia. Lancet 1989; 1: 363-366 DOI: 10.1016/s0140-6736(89)91733-9.
• 22 Jin JC, Lakkaraja MM, Ferd P. et al. Maternal sensitization occurs before delivery in severe cases of fetal alloimmune thrombocytopenia. Am J Hematol 2019; 94: E213-E215 DOI: 10.1002/ajh.25503.
• 23 Gruel Y, Boizard B, Daffos F. et al. Determination of platelet antigens and glycoproteins in the human fetus. Blood 1986; 68: 488-492 DOI: 10.1182/blood.V68.2.488.488.
• 24 Bennett JS. Structure and function of the platelet integrin alphaIIbbeta3. J Clin Invest 2005; 115: 3363-3369 DOI: 10.1172/JCI26989.
• 25 Kumpel BM, Sibley K, Jackson DJ. et al. Ultrastructural localization of glycoprotein III a (GPIIIa, β3 integrin) on placental syncytiotrophoblast microvilli: implications for platelet alloimmunization during pregnancy. Transfusion 2008; 48: 2077-2086 DOI: 10.1111/j.1537-2995.2008.01832.x.
• 26 Kjeldsen-Kragh J, Ahlen MT. Foetal and neonatal alloimmune thrombocytopenia – The role of the HLA-DRB3*01:01 allele for HPA-1a-immunisation and foetal/neonatal outcome. Transfus Apher Sci 2020; 59: 102707 DOI: 10.1016/j.transci.2019.102707.
• 27 Newman PJ, Derbes RS, Aster RH. The human platelet alloantigens, PlA1 and PlA2, are associated with a leucine33/proline33 amino acid polymorphism in membrane glycoprotein III a, and are distinguishable by DNA typing. J Clin Invest 1989; 83: 1778-1781 DOI: 10.1172/JCI114082.
• 28 Anani Sarab G, Moss M, Barker RN. et al. Naturally processed peptides spanning the HPA-1a polymorphism are efficiently generated and displayed from platelet glycoprotein by HLA-DRB3*0101-positive antigen-presenting cells. Blood 2009; 114: 1954-1957 DOI: 10.1182/blood-2009-04-211839.
• 29 Wienzek-Lischka S, König IR, Papenkort E-M. et al. HLA-DRB3*01:01 is a predictor of immunization against human platelet antigen-1a but not of the severity of fetal and neonatal alloimmune thrombocytopenia. Transfusion 2017; 57: 533-540 DOI: 10.1111/trf.13950.
• 30 Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007; 7: 715-725 DOI: 10.1038/nri2155.
• 31 Palmeira P, Quinello C, Silveira-Lessa AL. et al. IgG placental transfer in healthy and pathological pregnancies. Clin Dev Immunol 2012; 2012: 985646 DOI: 10.1155/2012/985646.
• 32 Santoso S, Wihadmadyatami H, Bakchoul T. et al. Antiendothelial αvβ3 Antibodies Are a Major Cause of Intracranial Bleeding in Fetal/Neonatal Alloimmune Thrombocytopenia. Arterioscler Thromb Vasc Biol 2016; 36: 1517-1524 DOI: 10.1161/ATVBAHA.116.307281.
• 33 Panzer S, Auerbach L, Cechova E. et al. Maternal alloimmunization against fetal platelet antigens: a prospective study. Br J Haematol 1995; 90: 655-660 DOI: 10.1111/j.1365-2141.1995.tb05597.x.
• 34 Sellers J, Thompson J, Guttridge MG. et al. Human platelet antigens: typing by PCR using sequence-specific primers and their distribution in blood donors resident in Wales. Eur J Immunogenet 1999; 26: 393-397 DOI: 10.1046/j.1365-2370.1999.00176.x.
• 35 Schnaidt M, Wernet D. Platelet-specific antibodies in female blood donors after pregnancy. Transfus Med 2000; 10: 77-80 DOI: 10.1046/j.1365-3148.2000.00234.x.
• 36 Kaplan C, Morel-Kopp MC, Kroll H. et al. HPA-5b (Br(a)) neonatal alloimmune thrombocytopenia: clinical and immunological analysis of 39 cases. Br J Haematol 1991; 78: 425-429 DOI: 10.1111/j.1365-2141.1991.tb04459.x.
• 37 Taaning E. HLA antibodies and fetomaternal alloimmune thrombocytopenia: myth or meaningful?. Transfus Med Rev 2000; 14: 275-280 DOI: 10.1053/tm.2000.7397.
• 38 Curtis BR, Fick A, Lochowicz AJ. et al. Neonatal alloimmune thrombocytopenia associated with maternal-fetal incompatibility for blood group B. Transfusion 2008; 48: 358-364 DOI: 10.1111/j.1537-2995.2007.01531.x.
• 39 Vos TW de Winkelhorst D. et al. Haas M de et al. Epidemiology and management of fetal and neonatal alloimmune thrombocytopenia. Transfus Apher Sci 2020; 59: 102704 DOI: 10.1016/j.transci.2019.102704.
• 40 Tiller H, Killie MK, Husebekk A. et al. Platelet antibodies and fetal growth: maternal antibodies against fetal platelet antigen 1a are strongly associated with reduced birthweight in boys. Acta Obstet Gynecol Scand 2012; 91: 79-86 DOI: 10.1111/j.1600-0412.2011.01269.x.
• 41 Delbos F, Bertrand G, Croisille L. et al. Fetal and neonatal alloimmune thrombocytopenia: predictive factors of intracranial hemorrhage. Transfusion 2016; 56: 59-66 quiz 58 DOI: 10.1111/trf.13274.
• 42 Bussel JB, Zacharoulis S, Kramer K. et al. Clinical and diagnostic comparison of neonatal alloimmune thrombocytopenia to non-immune cases of thrombocytopenia. Pediatr Blood Cancer 2005; 45: 176-183 DOI: 10.1002/pbc.20282.
• 43 Winkelhorst D, Kamphuis MM, Steggerda SJ. et al. Perinatal outcome and long-term neurodevelopment after intracranial haemorrhage due to fetal and neonatal alloimmune thrombocytopenia. Fetal Diagn Ther 2019; 45: 184-191 DOI: 10.1159/000488280.
• 44 Bonacossa IA, Jocelyn LJ. Alloimmune thrombocytopenia of the newborn: neurodevelopmental sequelae. Am J Perinatol 1996; 13: 211-215 DOI: 10.1055/s-2007-994366.
• 45 Radder CM, Brand A, Kanhai HHH. Will it ever be possible to balance the risk of intracranial haemorrhage in fetal or neonatal alloimmune thrombocytopenia against the risk of treatment strategies to prevent it?. Vox Sang 2003; 84: 318-325 DOI: 10.1046/j.1423-0410.2003.00302.x.
• 46 Dubruc E, Lebreton F, Giannoli C. et al. Placental histological lesions in fetal and neonatal alloimmune thrombocytopenia: A retrospective cohort study of 21 cases. Placenta 2016; 48: 104-109 DOI: 10.1016/j.placenta.2016.10.009.
• 47 Kiefel V, Santoso S, Weisheit M. et al. Monoclonal antibody – specific immobilization of platelet antigens (MAIPA): a new tool for the identification of platelet-reactive antibodies. Blood 1987; 70: 1722-1726
• 48 Campbell K, Rishi K, Howkins G. et al. A modified rapid monoclonal antibody-specific immobilization of platelet antigen assay for the detection of human platelet antigen (HPA) antibodies: a multicentre evaluation. Vox Sang 2007; 93: 289-297 DOI: 10.1111/j.1423-0410.2007.00989.x.
• 49 Menitove JE, Pereira J, Hoffman R. et al. Cyclic thrombocytopenia of apparent autoimmune etiology. Blood 1989; 73: 1561-1569
• 50 Nguyen XD, Goebel M, Schober M. et al. The detection of platelet antibodies by simultaneous analysis of specific platelet antibodies and the monoclonal antibody-specific immobilization of platelet antigens: an interlaboratory comparison. Transfusion 2010; 50: 1429-1434 DOI: 10.1111/j.1537-2995.2010.02610.x.
• 51 Uhrynowska M, Maslanka K, Zupanska B. Neonatal thrombocytopenia: incidence, serological and clinical observations. Am J Perinatol 1997; 14: 415-418 DOI: 10.1055/s-2007-994171.
• 52 Porcelijn L, Huiskes E, Comijs-van Osselen I. et al. A new bead-based human platelet antigen antibodies detection assay versus the monoclonal antibody immobilization of platelet antigens assay. Transfusion 2014; 54: 1486-1492 DOI: 10.1111/trf.12509.
• 53 Cooper N, Bein G, Heidinger K. et al. A bead-based assay in the work-up of suspected platelet alloimmunization. Transfusion 2016; 56: 115-118 DOI: 10.1111/trf.13351.
• 54 Holzwarth ST, Strobel J, Cooper N. et al. A point mutation c.473A G of ITGB3 is responsible for the formation of the Woa human platelet alloantigen. Transfusion 2020; 60: E5-E6 DOI: 10.1111/trf.15640.
• 55 Petermann R, Bakchoul T, Curtis BR. et al. Investigations for fetal and neonatal alloimmune thrombocytopenia: communication from the SSC of the ISTH. J Thromb Haemost 2018; 16: 2526-2529 DOI: 10.1111/jth.14294.
• 56 Bakchoul T, Kubiak S, Krautwurst A. et al. Low-avidity anti-HPA-1a alloantibodies are capable of antigen-positive platelet destruction in the NOD/SCID mouse model of alloimmune thrombocytopenia. Transfusion 2011; 51: 2455-2461 DOI: 10.1111/j.1537-2995.2011.03171.x.
• 57 Peterson JA, Kanack A, Nayak D. et al. Prevalence and clinical significance of low-avidity HPA-1a antibodies in women exposed to HPA-1a during pregnancy. Transfusion 2013; 53: 1309-1318 DOI: 10.1111/j.1537-2995.2012.03903.x.
• 58 Socher I, Zwingel C, Santoso S. et al. Heterogeneity of HPA-3 alloantibodies: consequences for the diagnosis of alloimmune thrombocytopenic syndromes. Transfusion 2008; 48: 463-472 DOI: 10.1111/j.1537-2995.2007.01550.x.
• 59 Harrison CR, Curtis BR, McFarland JG. et al. Severe neonatal alloimmune thrombocytopenia caused by antibodies to human platelet antigen 3a (Baka) detectable only in whole platelet assays. Transfusion 2003; 43: 1398-1402 DOI: 10.1046/j.1537-2995.2003.00533.x.
• 60 Ertel K, Al-Tawil M, Santoso S. et al. Relevance of the HPA-15 (Gov) polymorphism on CD109 in alloimmune thrombocytopenic syndromes. Transfusion 2005; 45: 366-373 DOI: 10.1111/j.1537-2995.2005.04281.x.
• 61 Schallmoser K, Kutschera J, Macher S. et al. Delayed detectability of anti-HPA-3a by the MAIPA assay in a severe neonatal alloimmune thrombocytopenia, but successful transfusion of incompatible donor platelets: a case report. Vox Sang 2006; 91: 181-183 DOI: 10.1111/j.1423-0410.2006.00809.x.